Healthcare

United Kingdom

We support clients across primary, acute, community, residential and social care including mental health, special education and children’s services. Our award winning healthcare team is well known for the innovative advice they offer on a wide range of healthcare matters from significant transactional advice to complex high value medical claims and healthcare regulatory advice, inward investment and NHS capital procurement, PFI’s, PPP’s and other healthcare outsourcings.

CMS are committed to driving development and growth in the sector and are members of key industry associations. We provide exceptional, tailored, expert and appropriately priced advice to a wide range of health and social care clients relying on our deep knowledge of the sector.

Long-standing clients include Nuffield Health, Spire Healthcare, NFA Group, Barchester Healthcare, Welltower, Care UK, HCA Healthcare, Primary Health Properties, General Optical Council, NHS Greater Glasgow & Clyde, Civitas Social Housing and BMI Healthcare.
 

Laing Buisson Award 2019

 

HI Award Logo 2018

 

 

Legal 500 UK Top Tier 2020

 

 

 

Read more Read less

"CMS' multi-disciplinary practice is spread across multiple offices and offers 'strong expertise' in high-value M&A transactional advice, international inward investment and NHS capital procurement, PFIs and PPP and other healthcare outsourcings."

The Legal 500, 2019
High­lights of our ex­per­i­ence in Health­care
Spire Health­care on a wide range of trans­ac­tions, in­clud­ing the dis­pos­al of two can­cer centres and the es­tab­lish­ment of a part­ner­ship with Gen­es­is Care. We also ad­vised on a cov­er­age dis­pute with its in­surer, RSA.Lloyds Bank Plc and West­min­ster Bank
Law-Now: Health­care
Vis­it Law-Now for leg­al know-how and com­ment­ary

Feed

Show only
13 January 2020
High­lights of our ex­per­i­ence in Health­care
28 July 2020
Mer­ck v Mer­ck: a les­son on the prac­tic­al im­plic­a­tions of co-ex­ist­ence agree­ments...
The High Court re­cently handed down a de­cision in the long-run­ning dis­pute between Mer­ck KGaA and Mer­ck Sharp & Dohme Corp and oth­ers in re­la­tion to use of the ‘Mer­ck’ name. A full ver­sion of the...
14 February 2017
Health Tech 2017: a case for great­er con­nec­tion
The health tech sec­tor is a mar­ket full of po­ten­tial in terms of both in­nov­a­tion and in­vest­ment. To bet­ter un­der­stand how key play­ers are in­volved in the de­vel­op­ment, man­u­fac­ture, pur­chas­ing, and util­isa­tion of health tech­no­logy, Nabarro com­mis­sioned a su
15 July 2020
New Scot­tish class ac­tion pro­ced­ure - how will the re­gime work? Part 1:...
Last month we re­por­ted on the new class ac­tion mech­an­ism that is be­ing in­tro­duced in Scot­land on 31 Ju­ly 2020 (see here).  The new mech­an­ism is in­ten­ded to bet­ter fa­cil­it­ate group claims.  It is be­ing...
06/02/2016
CMS launches Glob­al Product Li­ab­il­ity team in Lifes­ci­ences
14 July 2020
Santen ends Neur­im-style SPCs
The word­ing of Art­icle 3(d) of the SPC Reg­u­la­tion re­quires that the SPC ap­plic­a­tion must rely on “the first au­thor­isa­tion to place the product on the mar­ket as a medi­cin­al product”. This sug­gests...
15/12/2015
CMS Glob­al Lifes­ci­ences For­um Re­port 2015
26 June 2020
Court of Ap­peal re­fuses in­junc­tion in Neur­im v Mylan
We re­cently re­por­ted on the High Court judg­ment of Mr Justice Mar­cus Smith in Neur­im Phar­ma­ceut­ic­als (1991) Lim­ited and Flynn Pharma Lim­ited v Gen­er­ics UK Lim­ited (t/a Mylan) [2020] EWHC 1362 (Pat) in...
04/12/2015
The An­ti­dote - Winter 2015
25 June 2020
A look in­to the re­mote fu­ture
It has now been some three months since the sus­pen­sion of most reg­u­lat­ory hear­ings due to the Cov­id-19 pan­dem­ic. In that time in­ter­im or­der cases, pre-in­quest re­views, some re­view hear­ings and a num­ber...
09/09/2014
The An­ti­dote: Tak­ing a look at cor­por­ate in­ver­sions and e-Health
18 June 2020
MHRA re­leases up­dated guid­ance on med­ic­al device soft­ware and apps
On 4 June 2020, the Medi­cines and Health­care products Reg­u­lat­ory Agency (“MHRA”) pub­lished its up­dated guid­ance on med­ic­al device stand-alone soft­ware, which is in­ten­ded to cla­ri­fy the types of soft­ware...